AMARILLO, TX--(Marketwire - June 11, 2008) - Amarillo Biosciences, Inc. (OTCBB: AMAR), a specialty pharmaceutical company focused on low-dose orally administered interferon as a treatment for a variety of conditions, today announced that a patent has been filed with the United States Patent and Trademark Office on the oral use of interferon to treat obesity.
